Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 1.00 |
| ▸ | CCR3 | P51677 | 1/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.75 |
| ▸ | LTA4H | P09960 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2962629 | 1.00 | SIGMAR1 (1.00) | SIGMAR1CCR3POLBLTA4H | |
| SCHEMBL3593088 | 0.92 | SIGMAR1 (0.89) | SIGMAR1CCR3POLBLTA4H | |
| SCHEMBL11801794 | 0.92 | CCR3 (0.89) | SIGMAR1CCR3 | |
| SCHEMBL8092982 | 0.91 | SIGMAR1 (0.85) | SIGMAR1CCR3 | |
| SCHEMBL5302082 | 0.91 | LTA4H (0.86) | SIGMAR1CCR3POLBLTA4H | |
| SCHEMBL3633616 | 0.90 | SIGMAR1 (0.81) | SIGMAR1CCR3POLBLTA4H | |
| SCHEMBL11399131 | 0.90 | SIGMAR1 (0.81) | SIGMAR1CCR3POLBLTA4H | |
| SCHEMBL7329630 | 0.90 | SIGMAR1 (0.81) | SIGMAR1CCR3POLBLTA4H | |
| SCHEMBL14824971 | 0.90 | SIGMAR1 (0.81) | SIGMAR1CCR3POLBLTA4H | |
| SCHEMBL83687 | 0.90 | SIGMAR1 (0.86) | SIGMAR1CCR3POLBLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1014999-B1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GENZYME CORP (US) | 2004-12-08 | — | — | EP | claimed |
| CN-1270524-A | Cationic polymers as toxin binders | GELTEX PHARMA INC (US) | 2000-10-18 | — | — | CN | claimed |
| EP-1014999-A1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. (US) | 2000-07-05 | — | — | EP | claimed |
| US-6007803-A | ADMINISTERING TO MAMMAL A CATIONIC POLYMER TO INHIBIT PATHOGENIC TOXINS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-12-28 | — | — | US | claimed |
| WO-1999015186-A1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | claimed |
| EP-1014999-B1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GENZYME CORP (US) | 2004-12-08 | — | — | EP | disclosed |
| US-6692732-B2 | Administering cationic polymers to mammals to prevent poisons or antigens from microorganisms such as bacteria, viruses, fungi or parasites; deactivation | GENZYME CORPORATION | 2004-02-17 | — | — | US | disclosed |
| US-20040009145-A1 | IONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| US-20020114774-A1 | Ionic polymers as toxin-binding agents | GELTEX PHARMACEUTICALS, INC. | 2002-08-22 | — | — | US | disclosed |
| US-6290947-B1 | IN ONE EMBODIMENT, THE POLYMER IS A COPOLYMER COMPRISING A MONOMER HAVING A PENDANT AMMONIUM GROUP AND A HYDROPHOBIC MONOMER. | GELTEX PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| CN-1270524-A | Cationic polymers as toxin binders | GELTEX PHARMA INC (US) | 2000-10-18 | — | — | CN | disclosed |
| EP-1014999-A1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. (US) | 2000-07-05 | — | — | EP | disclosed |
| US-6007803-A | ADMINISTERING TO MAMMAL A CATIONIC POLYMER TO INHIBIT PATHOGENIC TOXINS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1999015186-A1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020114774-A1 | Ionic polymers as toxin-binding agents | PIGS, ANTXR2, MSN | SIGMAR1 2275/4885CCR3 575/4885POLB 3457/4885 |
| US-20040009145-A1 | IONIC POLYMERS AS TOXIN-BINDING AGENTS | PIGS, ANTXR2, MSN | SIGMAR1 2275/4885CCR3 575/4885POLB 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.